By employing CRISPR/Cas9 gene‐editing technology we successfully deleted EGFR, ERBB2, ERBB3, and ERBB4, respectively, in the human pancreatic cancer cell line Panc‐1. The gene discussed is EGFR; the disease is familial pancreatic carcinoma.